Please assess the completion status of the following clinical trial:

Trial Title: Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis Due to Chemoradiotherapy for Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects scheduled to be treated with (definitive or adjuvant) radiation therapy in combination with chemotherapy once daily for Stage 3A/3B or post-operative Stage 2B NSCLC or limited stage SCLC~2. Treatment plan for subjects show that 5 cm of the esophagus for at least one surface, is included in the 60 Gy isodose volume. Dose volume histograms show esophagus dose exposure meet V38\>30% and/or V60\>20%~3. Age 18 years or older~4. ECOG performance status ≤ 2~5. Adequate hematologic, renal and liver function~6. Use of highly effective contraception~Exclusion Criteria:~1. Metastatic disease~2. Prior radiation therapy to the region of the study cancer~3. Subjects not receiving chemotherapy~4. Grade 2 or greater esophagitis at baseline~5. Inability to provide information in the electronic symptom-reporting device~6. Receiving any approved or investigational immunotherapy, targeted therapy, hormone therapy, or biologic therapy~7. Participation in another clinical trial or use of another investigational agent within 30 days of first does of GC4419~8. Malignant tumors other than the current lung cancer within the last 5 years~9. Previous diagnosis of pneumonitis~10. Untreated, active infectious disease requiring systemic anti-infective therapy~11. Untreated HIV or active hepatitis B/C~12. Females who are pregnant or breastfeeding~13. Known allergies or intolerance to chemotherapy and similar platinum-containing compounds~14. Requirement for concurrent treatment with nitrates or other drugs that may create a risk for a precipitous decrease in blood pressure~15. Clinically significant heart disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GC4419 (avasopasem manganese) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).